Kahn JG

Global Mental Health, University of California San Francisco, San Francisco, CA, USA.

4 papers

ArticlePsychedelics

Well-being as a primary endpoint in clinical trials: a call for consensus.

Marseille E, Kettner H, Sgambati TJ +6

Europe PMC2026
ArticlePsilocybin

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.

Avanceña ALV, Vuong L, Kahn JG +1

Europe PMC2025
ArticlePsilocybin

Group psychedelic therapy: empirical estimates of cost-savings and improved access.

Marseille E, Stauffer CS, Agrawal M +5

Europe PMC2023
ArticlePsilocybin

The economics of psychedelic-assisted therapies: A research agenda.

Marseille E, Bertozzi S, Kahn JG

Europe PMC2022